Abbott’s latest innovation, the FreeStyle Libre® 2 Plus sensor, is available for the first time for t:slim X2™ insulin pump users in the U.S. Tandem’s Control-IQ™ hybrid closed-loop technology now ...

Abbott has secured a European approval for the newest generation of its FreeStyle Libre continuous glucose monitor—which the company describes as the world’s smallest and thinnest diabetes sensor, ...

Abbott has received CE Mark clearance for the second generation of its Freestyle Libre device, which will allow the company to make the device available to users in Europe. It will be rolled out ...

The FDA has approved the FreeStyle® Libre 2 integrated continuous glucose monitoring system (Abbott) for adults and children ≥4 years of age with diabetes. The Food and Drug Administration (FDA) has ...

“The addition of the Abbott FreeStyle Libre 2 Plus sensor to our CGM compatibility expands accessibility of Omnipod 5, which has been a priority for Insulet since the system launched in 2022,” said ...

At least seven fires and one injury that were related to some FreeStyle Libre glucose monitor products have led the US Food and Drug Administration to issue a Class I recall, the agency's strongest, ...

Abbott announced its next-generation, sensor-based glucose monitoring technology, FreeStyle Libre 2, received approval fromHealth Canada for adults and children (4 and older) with diabetes. With new ...

MISSISSAUGA, ON, July 8, 2025 /CNW/ -- Abbott (NYSE: ABT) today announced that its latest generation of sensor-based glucose monitoring technology, the FreeStyle Libre 3 Plus * sensor, is now ...

Omnipod 5 is the world’s first tubeless automated insulin delivery system to achieve CE mark approval with multiple continuous glucose monitoring (CGM) sensor brands. Latest Omnipod 5 integration is ...